Share on StockTwits

ZELTIQ Aesthetics (NASDAQ:ZLTQ) CEO Mark J. Foley sold 7,123 shares of ZELTIQ Aesthetics stock on the open market in a transaction that occurred on Wednesday, April 16th. The shares were sold at an average price of $18.05, for a total transaction of $128,570.15. Following the sale, the chief executive officer now directly owns 705,638 shares of the company’s stock, valued at approximately $12,736,766. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at Stifel Nicolaus initiated coverage on shares of ZELTIQ Aesthetics in a research note on Wednesday, March 19th. They set a “buy” rating and a $28.00 price target on the stock. Separately, analysts at Leerink Swann initiated coverage on shares of ZELTIQ Aesthetics in a research note on Friday, February 21st. They set an “outperform” rating and a $26.00 price target on the stock. Finally, analysts at Maxim Group raised their price target on shares of ZELTIQ Aesthetics from $16.00 to $25.00 in a research note on Tuesday, January 21st. They now have a “buy” rating on the stock. Two analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $23.11.

Shares of ZELTIQ Aesthetics (NASDAQ:ZLTQ) traded up 2.27% on Wednesday, hitting $18.05. 319,450 shares of the company’s stock traded hands. ZELTIQ Aesthetics has a 1-year low of $3.78 and a 1-year high of $24.79. The stock’s 50-day moving average is $18.4 and its 200-day moving average is $16.92. The company’s market cap is $671.6 million.

ZELTIQ Aesthetics (NASDAQ:ZLTQ) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($0.15) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.12) by $0.03. The company had revenue of $35.80 million for the quarter, compared to the consensus estimate of $33.28 million. Analysts expect that ZELTIQ Aesthetics will post $-0.36 EPS for the current fiscal year.

Zeltiq Aesthetics, Inc operates as a medical device development company. It engages in the design, development, and commercialization of non-invasive procedures for the reduction of unwanted fat tissue.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.